Prevalence of microalbuminuria in a hypertensive population of northern Navarre and its relation to other cardiovascular risk factors;Prevalencia de la microalbuminuria en una población hipertensa de Navarra septentrional y su relación con otros factores de riesgo cardiovascular

Anales del Sistema Sanitario de Navarra

Volumn 27, Issue 1, 2004, Pages 27-36

  Aguirre Echeverría, Benedicto ^a,b  

^a Centro de Salud de Elizondo   (Spain)

^b Centro de Salud de Elizondo   (Spain)

Author keywords

Arterial hypertension; Cardiovascular risk; Diabetes mellitus; Microalbuminuria

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DRINKING BEHAVIOR; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OBESITY; PREVALENCE; SMOKING; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; SPAIN;

EID: 2542503461     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. WOLF-MAIER K, COOPER RS, BANEGAS JR, GIAMPAOLI S, HENSE H-W, JOFFRES M et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
2. KANNEL WB. Blood presure as o cardiovascular risk factor. JAMA 1996; 275: 1571-1576.
3. PERERA GA. Hypertensive vascular disease: description and natural history. J Chronic Dis 1995; 1: 33-42.
4. PARVING HH, JENSEN HAE, MOGENSEN CE, EVRIN PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; 1: 1190-1192.
5. MOGENSEN CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254: 45-66.
6. BIANCHI S, BIGAZZI R, CAMPESE VM Microalbuminuria in esential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34: 973-975.
7. PALATINI P. Microalbuminuria in hypertension. Current hypertension reports 2003; 5: 208-214.
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
9. GOSSAIN VV, CARELLA MJ, ROVNER DR. Managemente of diabetes in the elderly: a clinical perspective. J Assoc Acad Minority Phys 1994; 5: 22-31.
10. HELDELBERG W. Pathogenesis, prevention, and treatment of diabetic nephropaty. Lancet 1998; 352: 213-219.
11. HORNYCH A, MARRE M, MIMRAN A, CHAIGNON A, ASMAR R, FAUVEL JP. Microalbuminuria in arterial hypertension. Measurement, variables, interpretation, recomendations. Arch Mal Coeur Vaiss 2000; 93: 1304-1308.
12. ROSA TT, PALATINI P. Clinical value of microalbuminuria in hypertension. J Hypertens 2000; 18: 645-654.
13. BONET J, VILA J, ALSINA MJ, ANCOCHEA L, ROMERO R. Prevalencia de microalbuminuria en la población general de un área mediterránea española y su asociación con otros factores de riesgo cardiovascular. Med Clin (Barc) 2001; 16: 573-574.
14. BIGAZZI R, BIANCHI S, CAMPESE VM, BALDARI G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 62: 120.
15. COTTONE S, CONTORNO A, NARDI E, ZAGARRIGO C, MANGANO MT, PANEPINTO N et al. Prevalence of microalbuminuria in recent-onset essential hypertension] Cardiologia 1993; 38: 733-736.
16. HOEGHOLM A, BANG LE, KRISTENSEN KS, NIELSEN JW, HOLM J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension. 1994; 24: 101-105.
17. REDON J, LIAO Y, LOZANO JV, MIRALLEs A, BALDO E, COOPER RS. Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 801-807.
18. PONTREMOLI R, CHELI V, SOFIA A, TIROTTA A, RAVERA M, NICOLELLA C et al. Prevalence of micro-and macroalbuminuria and their relationship with other cardiovascular risk factors in essential hypertension. Nephrol Dial Transplant 1995; 10: 6-9
19. SPANGLER JG, BELL RA, SUMMERSON JH, KONEN JC. Correlates of abnormal urinary albumin excretion rates among primary care patients with essential hypertension. J Am Board Fam Pract 1997; 10: 180-184.
20. MIMRAN A, RIBTEINJ, DUCAILER G. Microalbuminuria in essential hypertension. Cup Opin Nephrol Hypertens 1999; 8: 359-363.
21. TICKET J, VOL S, HALLAB M, CACES F, MARRE M. Epidemiology of microalbuminuria in a french population. J Diab Compl 1994; 8: 294-295.
22. GERSTEIN HC, MANN JFE, YI Q, ZINMAN B, DINNEEN SF, HOOGWERF B et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
23. MATOCK MB, MORRISH NJ, VIBERTI GC, KEEN H, FITGERALD AP. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41: 736-741.
24. ZAMORA A, MARRUGAT J. Pronóstico de los pacientes diabéticos con cardiopatía isquémica. Rev Esp Cardiol 2002; 55: 751-762.
25. SCHMITZ A, VAETH M, MOGENSEN CE. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 1994; 37: 1251-1258.
26. CAMPESE V, BIANCHI S, BIGAZZI R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int 1999; 71: S10-13.
27. HALIMI JM, FORHAN A, BALKAU B, NOVAK M, WILPART E, TICHET J et al. Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001; 8: 139-146.
28. GONZÁLEZ JR, ALEGRÍA E, GARCÍA JM, GONZÁLEZ I, VICENTE J. Impacto de la diabetes en las enfermedades cardíacas en España. Estudio CARDIOTENS. Med Clin (Barc) 2001; 116: 686-691.
29. MOLINA M, RABADÁN JA. Manual básico de nefrología para atención primaria. Murcia: Ed. La Gráfica, 2000.
30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355: 253-259.
31. HANSSON L, ZANCHETTI A, CARRUTHERS SG, DAHLOF B, ELMFELDT D, JULIUS S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
32. HERŃANDEZ H, BRITO O, DOMÍNGUEZ A, LUENGAS M, ALMADA J, HERNÁNDEZ H. Prevalencia de factores de riesgo coronario en pacientes hipertensos. Rev Mex Cardiol 1999; 10: 112-117.
33. ASSMANN G, SCHULTE H. The prospective cardiovascular Munster (PROCAM study): prevalence of hyperlipidemia in persons with hypertension and or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-1724.
34. PLAZA I, VILLAR F, MATA P, PÉREZ F, MAIQUEZ A, CASASNOVAS JA et al. Control de la colesterolemia en España. Un instrumento para la prevención cardiovascular. Rev Esp Cardiol 2000; 53: 815-837.
35. ARANDA P, BANEGAS JR, BARAJAS R, LUQUE M, RODICIO JL. Diagnosis and therapeutic management of hypercholesterolemic spanish hypertensives. J Hypertens 1999; 17 (Supl 3): 192.
36. KAYSEN GA. Hyperlipidemia of nephrotic syndrome. Kidney Int 1991; 39 (Suppl 31): S8-S15.
37. NEWMARK SR, ANDERSON CF, DONADIO JV, ELLEFSON RD. Lipoprotein profiles in adult nephrotic. Mayo Clin Proc 1975; 50: 359-366.
38. KLAHR S, SCHREINER G ICHIKAWA I. The progression of renal disease. N Engl J Med 1988; 318: 1657-1666.
39. KUUSISTO J, MIKKÄNEN L, PYÖRÄLÄ K, LAAKSO M. Hyperinsulinemic microalbuminuria. A new rosk indicator for coronary heart disease. Circulation 1995; 91: 831-837.
40. DOERKS GF, BOVEN AJ, HILLEGE HL, JANSEN WM, KORS JA, JONG PE et al. Microaluminuria was associated with ischemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of Renal and Vascular Endstage Disease). Eur Heart J 2000; 21: 1922-1927.
41. JENSEN JS, FELDT B, BORCH K, CLAUSEN P, APPLEYARD M, JENSEN G. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1.254 hypertensive individuals. J Hum Hypertens 1997; 11: 727-732.
42. PONTREMOLI R, SOFÍA A, RAVERA M, NICOLELLA C, VIAZZI F, TIROTTA A et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC study. Hypertension 1997; 30: 1135-1143.
43. STAESSEN JA, FAGARD R, THISS L. The systolic hypertension. Europe trial investigators. Morbidity and motality in the placebo controlled European trial of isolated systolic hypertension in the elderly. Lancet 1997; 360: 755-764.
44. APPLEGATE WB, SOWERS JR. Elevated systolic blood presure: increased cardiovascular risk and rationale for treatment. Am J Med 1996 (Supl. 3A): 3S-9S.
45. HAFFNER SM: Obesity and the metabolic sindrome: The San Antonio heart study. 44: Br J Nutr 2000; 83 (Supl 1): 67-70.
46. KANNEL WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000; 14: 83-90.
47. CHEN W, SRINIVASSAN SR, ELKASABANY A, BERENSON GS. The association of cardiovascular risk factor clustering related to insulin resistance syndrome between young parents and their offspring: The Bogalusa Heart Study. Atherosclerosis 1999; 145: 197-205.
48. SCHOLZE J, SHARMA AM. Treatment of hypertension in obesity. Herz 2001; 26: 209-221.
49. MULYADI L, STEVENS C, MUNRO S, LINGARD J, BERMINGHAM M. Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Ann Nutr Metab 2001; 45: 67-71.
50. AGRAWAL B, WOLF K, BERGER A, LUFT FC. Effect of antihypertensive drugs on microalbuminuria in non-diabetic patients with essential hypertension. J Hum Hypertens 1996; 10: 551-555.
51. ROVIRA E, JULVE R, PASCUAL JM, MIRALLES A, REDON J. Estudio de los factores relacionados con los cambios en la microalbuminuria durante el tratamiento antihipertensivo. Med Clin (Barc) 2000; 114: 721-725.
52. 2003 European society of hypertension-european society of cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-1053.